Compare Charles River Laboratories Intl. Inc (CRL) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Ecolab Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $228.98 (market cap $11.14B), while Ecolab Inc. trades at $269.19 (market cap $75.92B). The key difference: Ecolab Inc. is far larger — about 6.8× Charles River Laboratories Intl. Inc's market cap, and Ecolab Inc. pays a 1.08% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | ECL | |
|---|---|---|
Market Cap | $11.14B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $308.35 |
52-Week Low | $145.57 | $245.73 |
Enterprise Value | $14.00B | $84.66B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
ECL trades at $271.85, down 0.9% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.43, implying significant upside. Recent financials show revenue growth to $16.08B in 2025 and a net income margin of 12.8%, though earnings have been mixed with a Q2 2026 estimate of $2.08 pending. The company's acquisition of CoolIT for $4.75B strengthens its AI cooling portfolio, positioning it for long-term growth in high-tech markets.
The outlook for ECL is positive, supported by strong analyst buy ratings (75.68%) and strategic expansions, but risks include execution of recent acquisitions and cost pressures. The stock's current valuation multiples, such as a P/E of 36.79, suggest premium pricing that requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
